Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation
- PMID: 10433211
- DOI: 10.1210/endo.140.8.6887
Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation
Abstract
We studied the effects of PTH on the expression of tumor necrosis factor-related activation-induced cytokine (TRANCE), osteoprotegerin (OPG), and receptor activator of NF kappaB (RANK) messenger RNA (mRNA) in cultured murine bone marrow, calvaria, and osteoblasts. TRANCE, OPG, and RANK are recently identified regulators of osteoclast formation. Bone marrow cells were cultured with or without PTH(1-34) for 6 days. TRANCE, OPG, and RANK mRNA were measured by RT-PCR. In 6-day cultures, PTH stimulated the number of OCL/well in a dose-dependent manner. A time course showed significant (P < 0.01) increases in OCL/well after 24 h of PTH (100 ng/ml). TRANCE mRNA expression, like OCL formation, increased dose dependently and was maximal, with 10-100 ng/ml PTH. In contrast, OPG mRNA expression was decreased by 0.1 ng/ml PTH (40%) and completely abolished by 1 ng/ml. TRANCE mRNA expression was rapidly stimulated by PTH (maximal response at 1 h, 8.1-fold over control). Expression declined by 40% at 24 h but was still much greater than control at 6 days (4.6-fold) in a time-course study. PTH caused a transient stimulation of OPG mRNA at 1 h (2-fold), which returned to basal levels by 2 h. After 6 h, PTH completely inhibited OPG mRNA. There were only minor effects of PTH on RANK mRNA expression. PTH had less potent effects on TRANCE and OPG mRNA expression in calvaria organ cultures and osteoblasts. In mouse calvaria cultures, TRANCE expression was detectable in controls and was increased 2.9-fold by PTH at 24 h. PTH treatment of calvaria decreased OPG expression by 30% at 6 h. MC3T3 E-1 osteoblastic cells expressed minimal levels of TRANCE mRNA either before or after PTH treatment. OPG mRNA was present in MC3T3 E-1 cells, but levels were not modulated by PTH. In primary osteoblastic cells, PTH stimulated TRANCE mRNA expression 4-fold at 2 h and inhibited OPG mRNA expression by 46%. These results demonstrate a tight correlation between the ability of PTH to stimulate OCL formation in marrow culture and expression of TRANCE (r = 0.87, P < or = 0.05) and OPG mRNA (r = -0.88, P < or = 0.05). Reciprocal regulation of TRANCE and OPG mRNA by PTH preceded its effects on OCL formation by 18-23 h. Hence, it is likely that PTH regulates bone resorption, at least in part, via its effects on TRANCE and OPG expression.
Similar articles
-
Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells.J Bone Miner Res. 2002 Sep;17(9):1667-79. doi: 10.1359/jbmr.2002.17.9.1667. J Bone Miner Res. 2002. PMID: 12211438
-
Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors.J Bone Miner Res. 2000 Sep;15(9):1766-75. doi: 10.1359/jbmr.2000.15.9.1766. J Bone Miner Res. 2000. PMID: 10976996
-
PTH differentially regulates expression of RANKL and OPG.J Bone Miner Res. 2004 Feb;19(2):235-44. doi: 10.1359/JBMR.0301226. Epub 2003 Dec 16. J Bone Miner Res. 2004. PMID: 14969393
-
RANK-Fc: a therapeutic antagonist for RANK-L in myeloma.Cancer. 2003 Feb 1;97(3 Suppl):802-12. doi: 10.1002/cncr.11134. Cancer. 2003. PMID: 12548579 Review.
-
The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption.J Bone Miner Res. 2000 Jan;15(1):2-12. doi: 10.1359/jbmr.2000.15.1.2. J Bone Miner Res. 2000. PMID: 10646108 Review.
Cited by
-
Physiological Bone Remodeling: Systemic Regulation and Growth Factor Involvement.Physiology (Bethesda). 2016 May;31(3):233-45. doi: 10.1152/physiol.00061.2014. Physiology (Bethesda). 2016. PMID: 27053737 Free PMC article. Review.
-
Osteoprotegerin (OPG) and receptor activator of NF-kB ligand (RANK-L) serum levels in patients on chronic hemodialysis.J Endocrinol Invest. 2005 Jun;28(6):534-9. doi: 10.1007/BF03347242. J Endocrinol Invest. 2005. PMID: 16117195
-
Pathogenesis of postmenopausal osteoporosis.Rev Endocr Metab Disord. 2001 Jan;2(1):5-12. doi: 10.1023/a:1010074422268. Rev Endocr Metab Disord. 2001. PMID: 11704980 Review. No abstract available.
-
Osteitis fibrosa cystica masquerading as bone neoplasm.BMJ Case Rep. 2018 May 7;2018:bcr2018224546. doi: 10.1136/bcr-2018-224546. BMJ Case Rep. 2018. PMID: 29735505 Free PMC article.
-
Effect of parathyroidectomy on osteopontin and undercarboxylated osteocalcin in patients with primary hyperparathyroidism.Endocr Res. 2018 Feb;43(1):21-28. doi: 10.1080/07435800.2017.1369432. Epub 2017 Sep 22. Endocr Res. 2018. PMID: 28937873 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous